<code id='E1F04179C3'></code><style id='E1F04179C3'></style>
    • <acronym id='E1F04179C3'></acronym>
      <center id='E1F04179C3'><center id='E1F04179C3'><tfoot id='E1F04179C3'></tfoot></center><abbr id='E1F04179C3'><dir id='E1F04179C3'><tfoot id='E1F04179C3'></tfoot><noframes id='E1F04179C3'>

    • <optgroup id='E1F04179C3'><strike id='E1F04179C3'><sup id='E1F04179C3'></sup></strike><code id='E1F04179C3'></code></optgroup>
        1. <b id='E1F04179C3'><label id='E1F04179C3'><select id='E1F04179C3'><dt id='E1F04179C3'><span id='E1F04179C3'></span></dt></select></label></b><u id='E1F04179C3'></u>
          <i id='E1F04179C3'><strike id='E1F04179C3'><tt id='E1F04179C3'><pre id='E1F04179C3'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:knowledge    Page View:49558
          Sammy Kimball for STAT

          Can biotech startups survive a downturn? Is Covid-19 a good business? And when did ophthalmology get so dramatic?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss what some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

          advertisement

          For more on what we cover, here’s the news on Celsius Therapeutics; here’s more on EQRx; here’s the latest on Apellis Pharmaceuticals; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          focus

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          Anthos stroke drug appears safer than common blood thinner
          Anthos stroke drug appears safer than common blood thinner

          AdobePHILADELPHIA—Aninvestigationaldrugaimedatpreventingstrokessignificantlyreducedtheriskofbleeding

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Gain of function research would be limited under House proposal

          Rep.ThomasMassie(R-Ky.)KevinDietsch/GettyImagesWASHINGTON—HouselawmakerslateTuesdayvotedtoattachaU.S